Biotech | February 27, 2022
HitGen completes research collaboration with MTPC
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
Eubio Isoquercetin derived from Sophora Japonica is expected to deliver more Quercetin to the body via small doses of Isoquercetin.
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
Subscribe To Our Newsletter & Stay Updated
